

Silvia Mezi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9453513/publications.pdf>

Version: 2024-02-01

43
papers

1,509
citations

567281

15
h-index

330143

37
g-index

43
all docs

43
docs citations

43
times ranked

2698
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase 2 of coronavirus disease (COVID-19) and head and neck cancer: An action plan. <i>Oral Diseases</i> , 2022, 28, 970-972.	3.0	1
2	Management of a rare case of squamous cell carcinoma of the tongue in a patient affected by progeria. <i>Oral Oncology</i> , 2021, 113, 105032.	1.5	1
3	A New Medical Record Proposal to the Prognostic Risk Assessment for MRONJ in Oncologic Patients: "Sapienza Head and Neck Unit" Proposal. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 1851.	2.6	2
4	Standard of Care and Promising New Agents for the Treatment of Mesenchymal Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 1080.	3.7	10
5	The role of opioids in cancer response to immunotherapy. <i>Journal of Translational Medicine</i> , 2021, 19, 119.	4.4	24
6	Weekly chemotherapy as first line treatment in frail head and neck cancer patients in the immunotherapy era. <i>Journal of Translational Medicine</i> , 2021, 19, 303.	4.4	1
7	The Role of Soluble LAG3 and Soluble Immune Checkpoints Profile in Advanced Head and Neck Cancer: A Pilot Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 651.	2.5	28
8	Anti-PD-1 and Anti-PD-L1 in Head and Neck Cancer: A Network Meta-Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 705096.	4.8	47
9	Prediction of Recurrence by Machine Learning in Salivary Gland Cancer Patients After Adjuvant (Chemo)Radiotherapy. <i>In Vivo</i> , 2021, 35, 3355-3360.	1.3	3
10	Tissue Immune Profile: A Tool to Predict Response to Neoadjuvant Therapy in Triple Negative Breast Cancer. <i>Cancers</i> , 2020, 12, 2648.	3.7	10
11	Primary squamous cell carcinoma of major salivary gland: "Sapienza Head and Neck Unit" clinical recommendations. <i>Rare Tumors</i> , 2020, 12, 203636132097352.	0.6	12
12	The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with Immunotherapy. <i>Vaccines</i> , 2020, 8, 203.	4.4	38
13	Clinical Multigene Panel Sequencing Identifies Distinct Mutational Association Patterns in Metastatic Colorectal Cancer. <i>Frontiers in Oncology</i> , 2020, 10, 560.	2.8	12
14	Tobacco, Alcohol and Family History of Cancer as Risk Factors of Oral Squamous Cell Carcinoma: Case-Control Retrospective Study. <i>Applied Sciences (Switzerland)</i> , 2020, 10, 3896.	2.5	26
15	Efficacy and Tolerability of Selective Internal Radiotherapy With Yttrium-90 as Consolidation Treatment After Chemotherapy in Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2020, 19, e272-e276.	2.3	1
16	The 5-Ws of immunotherapy in head and neck cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 153, 103041.	4.4	13
17	Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1. <i>Frontiers in Immunology</i> , 2020, 11, 1243.	4.8	30
18	The Impact of Locoregional Treatment on Response to Nivolumab in Advanced Platinum Refractory Head and Neck Cancer: The Need Trial. <i>Vaccines</i> , 2020, 8, 191.	4.4	10

#	ARTICLE	IF	CITATIONS
19	A combined genomic and immune profile in patients with head and neck squamous cell carcinoma treated with immunotherapy: A pilot study.. Journal of Clinical Oncology, 2020, 38, e18506-e18506.	1.6	0
20	The impact of locoregional treatment on response to nivolumab in advanced platinum refractory head and neck cancer: The need trial.. Journal of Clinical Oncology, 2020, 38, e18508-e18508.	1.6	0
21	Induction chemotherapy in nonlaryngeal human papilloma virus-negative high-risk head and neck cancer: a real-world experience. Anti-Cancer Drugs, 2020, 31, 1074-1083.	1.4	1
22	A Simplified Genomic Profiling Approach Predicts Outcome in Metastatic Colorectal Cancer. Cancers, 2019, 11, 147.	3.7	15
23	Advances in the Management of HPV-Related Oropharyngeal Cancer. Journal of Oncology, 2019, 2019, 1-8.	1.3	34
24	Sinonasal Undifferentiated Carcinoma in a Patient Previously Treated for an Intestinal-Type Adenocarcinoma: Metachronous Neoplasms or Recurrence of a Different Tumor Type?. Indian Journal of Otolaryngology and Head and Neck Surgery, 2019, 71, 1779-1781.	0.9	3
25	Implant placement in oral squamous cells carcinoma patients treated with chemoradiotherapy: "Sapienza Head and Neck Unit" clinical recommendations. European Review for Medical and Pharmacological Sciences, 2019, 23, 9923-9930.	0.7	2
26	Aesthetic satisfaction in lip and palate clefts: a comparative study between secondary and tertiary bone grafting. Clinica Terapeutica, 2018, 169, e62-e66.	0.3	3
27	Follow-up program in head and neck cancer. Critical Reviews in Oncology/Hematology, 2017, 113, 151-155.	4.4	49
28	Management of salivary gland malignant tumor: the Policlinico Umberto I, "Sapienza" University of Rome Head and Neck Unit clinical recommendations. Critical Reviews in Oncology/Hematology, 2017, 120, 93-97.	4.4	17
29	Clinical significance of epithelial-to-mesenchymal transition in laryngeal carcinoma: Its role in the different subsites. Head and Neck, 2017, 39, 1806-1818.	2.0	15
30	Radioembolization (SIRT) as a consolidation treatment in colorectal liver metastases after first line chemotherapy.. Journal of Clinical Oncology, 2016, 34, e15007-e15007.	1.6	0
31	BRAFV600E mutation positive metastatic melanoma in a young woman treated with anti-BRAF/anti MEK combination: a case report. Journal of Translational Medicine, 2015, 13, P8.	4.4	0
32	FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncology, The, 2015, 16, 1306-1315.	10.7	835
33	Standard of Care and Promising New Agents for Triple Negative Metastatic Breast Cancer. Cancers, 2014, 6, 2187-2223.	3.7	34
34	Management of Metastatic Renal Cell Carcinoma Progressed After Sunitinib or Another Antiangiogenic Treatment. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 611-615.	1.3	11
35	Incidence and relative risk of hepatic toxicity in patients treated with anti-angiogenic tyrosine kinase inhibitors for malignancy. British Journal of Clinical Pharmacology, 2014, 77, 929-938.	2.4	65
36	Incidence of thromboembolic events in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy. Acta Oncologica, 2013, 52, 187-190.	1.8	12

#	ARTICLE	IF	CITATIONS
37	Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials. <i>Acta Oncologica</i> , 2012, 51, 873-879.	1.8	66
38	Involvement of the Src-cortactin pathway in migration induced by IGF-1 and EGF in human breast cancer cells. <i>International Journal of Oncology</i> , 2012, 41, 2128-2138.	3.3	36
39	Neuroendocrine tumors of the gallbladder: a case report and review of the literature. <i>Journal of Medical Case Reports</i> , 2011, 5, 334.	0.8	27
40	Somatostatin receptor scintigraphy in metastatic breast cancer patients. <i>Oncology Reports</i> , 2005, 13, 31-5.	2.6	4
41	In vivo detection of resistance to anthracycline based neoadjuvant chemotherapy in locally advanced and inflammatory breast cancer with technetium-99m sestamibi scintimammography. <i>International Journal of Oncology</i> , 2003, 22, 1233.	3.3	5
42	In vivo detection of resistance to anthracycline based neoadjuvant chemotherapy in locally advanced and inflammatory breast cancer with technetium-99m sestamibi scintimammography. <i>International Journal of Oncology</i> , 2003, 22, 1233-40.	3.3	4
43	Somatostatin receptor scintigraphy in metastatic breast cancer patients. <i>Oncology Reports</i> , 0, , .	2.6	2